Health and economic impact of rotavirus vaccination in GAVI-eligible countries

BMC Public Health

Table 6 Budget impact of alternative scale-up scenarios in the GAVI-eligible countries

			Financial costs^a
No	Scale-up scenarios	No. of children vaccinated	Global society perspective (Total vaccination program costs)	GAVI Alliance perspective (Vaccine cost support)	Local government perspective (not including medical cost savings)^b	Local government perspective (including medical cost savings)^b
		(in million)	(US$, million)	(US$, million)	(US$, million)	(US$, million)
1	Base-case rollout scenario (Table 2)
	Vaccine efficacy based on the SAGE approach
	Vaccine immunity waning (14% annually)	281.8	5,879	4,079	1,800	1,714
2	Base-case rollout scenario (Table 2)
	Vaccine efficacy based on the SAGE approach
	No vaccine immunity waning	281.8	5,879	4,079	1,800	1,707
3	Base-case rollout scenario (Table 2)
	Vaccine efficacy adjusted for serotype distribution
	Vaccine immunity waning (14% annually)	281.8	5,879	4,079	1,800	1,695
4^c	Base-case rollout scenario (Table 2)
	Vaccine efficacy adjusted for serotype distribution
	No vaccine immunity waning	281.8	5,879	4,079	1,800	1,686
5	(Modified) Wolfson et al. scenario [30]
	Vaccine efficacy based on the SAGE approach
	No vaccine immunity waning	410.5	8,573	5,943	2,630	2,472
6	(Modified) Wolfson et al. scenario [30]
	Vaccine efficacy adjusted for serotype distribution
	No vaccine immunity waning	410.5	8,573	5,943	2,630	2,414
7	A flat coverage of 70%
	Vaccine efficacy based on the SAGE approach
	No vaccine immunity waning	537.0	11,222	7,785	3,437	3,236
8	A flat coverage of 70%
	Vaccine efficacy adjusted for serotype distribution
	No vaccine immunity waning	537.0	11,222	7,785	3,437	3,170

r = discount rate; YL = years of life; DALYs = disability-adjusted life-years; I$ = international dollars; SAGE = Strategic Advisory Group of Experts on Immunization.
a All 10-year forecasts are based on the composite program cost of I$25 (corresponding to US$5 per vaccine dose) per vaccinated child and are not discounted.
b The vaccine costs to local governments are based on the GAVI's co-financing scheme [32].
c Base-case analysis.

ISSN: 1471-2458